Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics of AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function
Conditions
Interventions
AMG 133
Locations
5
United States
Clinical Pharmacology Of Miami, LLC
Miami, Florida, United States
Panax Clinical Research
Miami Lakes, Florida, United States
Orlando Clinical Research Center
Orlando, Florida, United States
The Texas Liver Institute, Inc.
San Antonio, Texas, United States
Pinnacle Clinical Research San Antonio
San Antonio, Texas, United States
Start Date
March 14, 2025
Primary Completion Date
February 26, 2026
Completion Date
February 26, 2026
Last Updated
March 11, 2026
NCT07324616
NCT04271488
NCT05484206
NCT06952634
NCT06841315
NCT06619054
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions